aluates Reports

$ 0.0

Automative

Global Follicular Lymphoma Drugs Market Research Report 2025

Published Date: March 2025

Report Code: QYRE-Auto-7Z9384

Global Follicular Lymphoma Drugs Market Insights and Forecast to 2028

BUY CHAPTERS

Global Follicular Lymphoma Drugs Market Research Report 2025

Code: QYRE-Auto-7Z9384

Report

March 2025

Pages:92

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Gilead Sciences

Secura Bio

EpiZyme Inc

Eisai Co Ltd

Acrotech Biopharma

TEVA

Eagle Pharmaceuticals

Mundipharma

Bayer

BeiGene Ltd

Pfizer Inc

Novartis

Bristol–Myers Squibb

JW Therapeutics

FOSUNKite

Follicular Lymphoma Drugs Market Size

The global market for Follicular Lymphoma Drugs was valued at US$ 1972 million in the year 2024 and is projected to reach a revised size of US$ 3227 million by 2031, growing at a CAGR of 7.4% during the forecast period.

Follicular Lymphoma Drugs Market

Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.

The follicular lymphoma drugs market is primarily driven by the increasing prevalence of follicular lymphoma (FL), a common and slow-growing form of non-Hodgkin lymphoma. As the global population ages, the incidence of FL is expected to rise, which boosts demand for effective treatments. Additionally, recent advancements in targeted therapies, including monoclonal antibodies like rituximab and the development of novel small molecules, have significantly improved patient outcomes and survival rates. The growing adoption of combination therapies, such as chemotherapy paired with targeted treatments or immunotherapies, has further expanded treatment options and contributed to the market's growth. The emergence of personalized medicine also enhances the potential for more tailored, effective therapies.

On the other hand, the follicular lymphoma drugs market faces challenges, including the high cost of cutting-edge therapies. Treatments such as CAR-T cell therapy and novel biologics, while effective, can be expensive and limit patient access, particularly in lower-income regions. Additionally, although FL is typically slow-growing, it is also highly recurrent, requiring long-term management and monitoring, which can strain healthcare systems. The risk of resistance to existing therapies, along with concerns over the long-term side effects of certain treatments, further complicates the landscape. Regulatory hurdles for the approval of new drugs, along with the need for ongoing research into optimizing treatment regimens, present further challenges in meeting the diverse needs of FL patients.

Global core follicular lymphoma drugs players include Roche, Teva and Bayer etc. The Top3 companies hold a share about 57%. North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.

This report aims to provide a comprehensive presentation of the global market for Follicular Lymphoma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Follicular Lymphoma Drugs.

The Follicular Lymphoma Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Follicular Lymphoma Drugs market comprehensively. Regional market sizes, concerning products by Type, by Administration Route, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Follicular Lymphoma Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Administration Route, and by regions.

Market Segmentation

Scope of Follicular Lymphoma Drugs Market Report

Report Metric	Details
Report Name	Follicular Lymphoma Drugs Market
Accounted market size in year	US$ 1972 million
Forecasted market size in 2031	US$ 3227 million
CAGR	7.4%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Anti-CD20 mAbs Chemotherapy Agents Kinase Inhibitor Others
Segment by Administration Route	Injection Oral
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Gilead Sciences, Beigene, Bayer, Secura Bio, Epizyme, Eisai, Acrotech Biopharma, Teva, Eagle Pharmaceuticals, MundiPharma, Pfizer, Novartis, Bristol-Myers Squibb, JW Therapeutics, FOSUNKite
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Administration Route, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Follicular Lymphoma Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Administration Route, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Follicular Lymphoma Drugs Market growing?

Ans: The Follicular Lymphoma Drugs Market witnessing a CAGR of 7.4% during the forecast period 2025-2031.

What is the Follicular Lymphoma Drugs Market size in 2031?

Ans: The Follicular Lymphoma Drugs Market size in 2031 will be US$ 3227 million.

What is the Follicular Lymphoma Drugs Market share by region?

Ans: North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.

Who are the main players in the Follicular Lymphoma Drugs Market report?

Ans: The main players in the Follicular Lymphoma Drugs Market are Roche, Gilead Sciences, Beigene, Bayer, Secura Bio, Epizyme, Eisai, Acrotech Biopharma, Teva, Eagle Pharmaceuticals, MundiPharma, Pfizer, Novartis, Bristol-Myers Squibb, JW Therapeutics, FOSUNKite

What are the Type segmentation covered in the Follicular Lymphoma Drugs Market report?

Ans: The Types covered in the Follicular Lymphoma Drugs Market report are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, Others

Recommended Reports

Lymphoma Treatments

Leukemia Drugs

Hematologic Malignancy

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Follicular Lymphoma Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Anti-CD20 mAbs

1.2.3 Chemotherapy Agents

1.2.4 Kinase Inhibitor

1.2.5 Others

1.3 Market by Administration Route

1.3.1 Global Follicular Lymphoma Drugs Market Growth by Administration Route: 2020 VS 2024 VS 2031

1.3.2 Injection

1.3.3 Oral

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Follicular Lymphoma Drugs Market Perspective (2020-2031)

2.2 Global Follicular Lymphoma Drugs Growth Trends by Region

2.2.1 Global Follicular Lymphoma Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Follicular Lymphoma Drugs Historic Market Size by Region (2020-2025)

2.2.3 Follicular Lymphoma Drugs Forecasted Market Size by Region (2026-2031)

2.3 Follicular Lymphoma Drugs Market Dynamics

2.3.1 Follicular Lymphoma Drugs Industry Trends

2.3.2 Follicular Lymphoma Drugs Market Drivers

2.3.3 Follicular Lymphoma Drugs Market Challenges

2.3.4 Follicular Lymphoma Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Follicular Lymphoma Drugs Players by Revenue

3.1.1 Global Top Follicular Lymphoma Drugs Players by Revenue (2020-2025)

3.1.2 Global Follicular Lymphoma Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Follicular Lymphoma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Follicular Lymphoma Drugs Revenue

3.4 Global Follicular Lymphoma Drugs Market Concentration Ratio

3.4.1 Global Follicular Lymphoma Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Follicular Lymphoma Drugs Revenue in 2024

3.5 Global Key Players of Follicular Lymphoma Drugs Head office and Area Served

3.6 Global Key Players of Follicular Lymphoma Drugs, Product and Application

3.7 Global Key Players of Follicular Lymphoma Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Follicular Lymphoma Drugs Breakdown Data by Type

4.1 Global Follicular Lymphoma Drugs Historic Market Size by Type (2020-2025)

4.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2026-2031)

5 Follicular Lymphoma Drugs Breakdown Data by Administration Route

5.1 Global Follicular Lymphoma Drugs Historic Market Size by Administration Route (2020-2025)

5.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2026-2031)

6 North America

6.1 North America Follicular Lymphoma Drugs Market Size (2020-2031)

6.2 North America Follicular Lymphoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Follicular Lymphoma Drugs Market Size by Country (2020-2025)

6.4 North America Follicular Lymphoma Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Follicular Lymphoma Drugs Market Size (2020-2031)

7.2 Europe Follicular Lymphoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Follicular Lymphoma Drugs Market Size by Country (2020-2025)

7.4 Europe Follicular Lymphoma Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Follicular Lymphoma Drugs Market Size (2020-2031)

8.2 Asia-Pacific Follicular Lymphoma Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Follicular Lymphoma Drugs Market Size (2020-2031)

9.2 Latin America Follicular Lymphoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Follicular Lymphoma Drugs Market Size by Country (2020-2025)

9.4 Latin America Follicular Lymphoma Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Follicular Lymphoma Drugs Market Size (2020-2031)

10.2 Middle East & Africa Follicular Lymphoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Details

11.1.2 Roche Business Overview

11.1.3 Roche Follicular Lymphoma Drugs Introduction

11.1.4 Roche Revenue in Follicular Lymphoma Drugs Business (2020-2025)

11.1.5 Roche Recent Development

11.2 Gilead Sciences

11.2.1 Gilead Sciences Company Details

11.2.2 Gilead Sciences Business Overview

11.2.3 Gilead Sciences Follicular Lymphoma Drugs Introduction

11.2.4 Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2020-2025)

11.2.5 Gilead Sciences Recent Development

11.3 TG Therapeutics

11.3.1 TG Therapeutics Company Details

11.3.2 TG Therapeutics Business Overview

11.3.3 TG Therapeutics Follicular Lymphoma Drugs Introduction

11.3.4 TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2020-2025)

11.3.5 TG Therapeutics Recent Development

11.4 Bayer

11.4.1 Bayer Company Details

11.4.2 Bayer Business Overview

11.4.3 Bayer Follicular Lymphoma Drugs Introduction

11.4.4 Bayer Revenue in Follicular Lymphoma Drugs Business (2020-2025)

11.4.5 Bayer Recent Development

11.5 Secura Bio

11.5.1 Secura Bio Company Details

11.5.2 Secura Bio Business Overview

11.5.3 Secura Bio Follicular Lymphoma Drugs Introduction

11.5.4 Secura Bio Revenue in Follicular Lymphoma Drugs Business (2020-2025)

11.5.5 Secura Bio Recent Development

11.6 Epizyme

11.6.1 Epizyme Company Details

11.6.2 Epizyme Business Overview

11.6.3 Epizyme Follicular Lymphoma Drugs Introduction

11.6.4 Epizyme Revenue in Follicular Lymphoma Drugs Business (2020-2025)

11.6.5 Epizyme Recent Development

11.7 Eisai

11.7.1 Eisai Company Details

11.7.2 Eisai Business Overview

11.7.3 Eisai Follicular Lymphoma Drugs Introduction

11.7.4 Eisai Revenue in Follicular Lymphoma Drugs Business (2020-2025)

11.7.5 Eisai Recent Development

11.8 Acrotech Biopharma

11.8.1 Acrotech Biopharma Company Details

11.8.2 Acrotech Biopharma Business Overview

11.8.3 Acrotech Biopharma Follicular Lymphoma Drugs Introduction

11.8.4 Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2020-2025)

11.8.5 Acrotech Biopharma Recent Development

11.9 Teva

11.9.1 Teva Company Details

11.9.2 Teva Business Overview

11.9.3 Teva Follicular Lymphoma Drugs Introduction

11.9.4 Teva Revenue in Follicular Lymphoma Drugs Business (2020-2025)

11.9.5 Teva Recent Development

11.10 Eagle Pharmaceuticals

11.10.1 Eagle Pharmaceuticals Company Details

11.10.2 Eagle Pharmaceuticals Business Overview

11.10.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Introduction

11.10.4 Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2020-2025)

11.10.5 Eagle Pharmaceuticals Recent Development

11.11 MundiPharma

11.11.1 MundiPharma Company Details

11.11.2 MundiPharma Business Overview

11.11.3 MundiPharma Follicular Lymphoma Drugs Introduction

11.11.4 MundiPharma Revenue in Follicular Lymphoma Drugs Business (2020-2025)

11.11.5 MundiPharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Roche

Gilead Sciences

Secura Bio

EpiZyme Inc

Eisai Co Ltd

Acrotech Biopharma

TEVA

Eagle Pharmaceuticals

Mundipharma

Bayer

BeiGene Ltd

Pfizer Inc

Novartis

Bristol–Myers Squibb

JW Therapeutics

FOSUNKite

List of Tables

Table 1. Global Follicular Lymphoma Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Anti-CD20 mAbs

Table 3. Key Players of Chemotherapy Agents

Table 4. Key Players of Kinase Inhibitor

Table 5. Key Players of Others

Table 6. Global Follicular Lymphoma Drugs Market Size Growth by Administration Route (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Follicular Lymphoma Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Follicular Lymphoma Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Follicular Lymphoma Drugs Market Share by Region (2020-2025)

Table 10. Global Follicular Lymphoma Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Follicular Lymphoma Drugs Market Share by Region (2026-2031)

Table 12. Follicular Lymphoma Drugs Market Trends

Table 13. Follicular Lymphoma Drugs Market Drivers

Table 14. Follicular Lymphoma Drugs Market Challenges

Table 15. Follicular Lymphoma Drugs Market Restraints

Table 16. Global Follicular Lymphoma Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Follicular Lymphoma Drugs Market Share by Players (2020-2025)

Table 18. Global Top Follicular Lymphoma Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Follicular Lymphoma Drugs as of 2024)

Table 19. Ranking of Global Top Follicular Lymphoma Drugs Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Follicular Lymphoma Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Follicular Lymphoma Drugs, Headquarters and Area Served

Table 22. Global Key Players of Follicular Lymphoma Drugs, Product and Application

Table 23. Global Key Players of Follicular Lymphoma Drugs, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Follicular Lymphoma Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2020-2025)

Table 27. Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2026-2031)

Table 29. Global Follicular Lymphoma Drugs Market Size by Administration Route (2020-2025) & (US$ Million)

Table 30. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2020-2025)

Table 31. Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2026-2031) & (US$ Million)

Table 32. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2026-2031)

Table 33. North America Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Follicular Lymphoma Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Follicular Lymphoma Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Follicular Lymphoma Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Follicular Lymphoma Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Follicular Lymphoma Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Follicular Lymphoma Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Follicular Lymphoma Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 48. Roche Company Details

Table 49. Roche Business Overview

Table 50. Roche Follicular Lymphoma Drugs Product

Table 51. Roche Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)

Table 52. Roche Recent Development

Table 53. Gilead Sciences Company Details

Table 54. Gilead Sciences Business Overview

Table 55. Gilead Sciences Follicular Lymphoma Drugs Product

Table 56. Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)

Table 57. Gilead Sciences Recent Development

Table 58. TG Therapeutics Company Details

Table 59. TG Therapeutics Business Overview

Table 60. TG Therapeutics Follicular Lymphoma Drugs Product

Table 61. TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)

Table 62. TG Therapeutics Recent Development

Table 63. Bayer Company Details

Table 64. Bayer Business Overview

Table 65. Bayer Follicular Lymphoma Drugs Product

Table 66. Bayer Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)

Table 67. Bayer Recent Development

Table 68. Secura Bio Company Details

Table 69. Secura Bio Business Overview

Table 70. Secura Bio Follicular Lymphoma Drugs Product

Table 71. Secura Bio Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)

Table 72. Secura Bio Recent Development

Table 73. Epizyme Company Details

Table 74. Epizyme Business Overview

Table 75. Epizyme Follicular Lymphoma Drugs Product

Table 76. Epizyme Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)

Table 77. Epizyme Recent Development

Table 78. Eisai Company Details

Table 79. Eisai Business Overview

Table 80. Eisai Follicular Lymphoma Drugs Product

Table 81. Eisai Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)

Table 82. Eisai Recent Development

Table 83. Acrotech Biopharma Company Details

Table 84. Acrotech Biopharma Business Overview

Table 85. Acrotech Biopharma Follicular Lymphoma Drugs Product

Table 86. Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)

Table 87. Acrotech Biopharma Recent Development

Table 88. Teva Company Details

Table 89. Teva Business Overview

Table 90. Teva Follicular Lymphoma Drugs Product

Table 91. Teva Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)

Table 92. Teva Recent Development

Table 93. Eagle Pharmaceuticals Company Details

Table 94. Eagle Pharmaceuticals Business Overview

Table 95. Eagle Pharmaceuticals Follicular Lymphoma Drugs Product

Table 96. Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)

Table 97. Eagle Pharmaceuticals Recent Development

Table 98. MundiPharma Company Details

Table 99. MundiPharma Business Overview

Table 100. MundiPharma Follicular Lymphoma Drugs Product

Table 101. MundiPharma Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)

Table 102. MundiPharma Recent Development

Table 103. Research Programs/Design for This Report

Table 104. Key Data Information from Secondary Sources

Table 105. Key Data Information from Primary Sources

Table 106. Authors List of This Report

List of Figures

Figure 1. Follicular Lymphoma Drugs Picture

Figure 2. Global Follicular Lymphoma Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Follicular Lymphoma Drugs Market Share by Type: 2024 VS 2031

Figure 4. Anti-CD20 mAbs Features

Figure 5. Chemotherapy Agents Features

Figure 6. Kinase Inhibitor Features

Figure 7. Others Features

Figure 8. Global Follicular Lymphoma Drugs Market Size by Administration Route (2020-2031) & (US$ Million)

Figure 9. Global Follicular Lymphoma Drugs Market Share by Administration Route: 2024 VS 2031

Figure 10. Injection Case Studies

Figure 11. Oral Case Studies

Figure 12. Follicular Lymphoma Drugs Report Years Considered

Figure 13. Global Follicular Lymphoma Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Follicular Lymphoma Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Follicular Lymphoma Drugs Market Share by Region: 2024 VS 2031

Figure 16. Global Follicular Lymphoma Drugs Market Share by Players in 2024

Figure 17. Global Top Follicular Lymphoma Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Follicular Lymphoma Drugs as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Follicular Lymphoma Drugs Revenue in 2024

Figure 19. North America Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Follicular Lymphoma Drugs Market Share by Country (2020-2031)

Figure 21. United States Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Follicular Lymphoma Drugs Market Share by Country (2020-2031)

Figure 25. Germany Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Follicular Lymphoma Drugs Market Share by Region (2020-2031)

Figure 33. China Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Follicular Lymphoma Drugs Market Share by Country (2020-2031)

Figure 41. Mexico Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Follicular Lymphoma Drugs Market Share by Country (2020-2031)

Figure 45. Turkey Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Roche Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)

Figure 49. Gilead Sciences Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)

Figure 50. TG Therapeutics Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)

Figure 51. Bayer Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)

Figure 52. Secura Bio Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)

Figure 53. Epizyme Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)

Figure 54. Eisai Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)

Figure 55. Acrotech Biopharma Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)

Figure 56. Teva Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)

Figure 57. Eagle Pharmaceuticals Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)

Figure 58. MundiPharma Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Hodgkin s Lymphoma Drugs Market Research Report 2024

Global Chronic Lymphocytic Leukemia Drugs Market Research Report 2024

Global Follicular Thyroid Cancer Drug Market Research Report 2025

Global Targeted Drug for Blood Cancers Market Research Report 2024

Blood Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Non Hodgkin Lymphoma Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Follicular Lymphoma Treatment Market Research Report 2025

B Cell Non Hodgkin s Lymphoma Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Non Hodgkin s Lymphoma Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Non Hodgkin Lymphoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Blood Tumor Drugs Market Research Report 2024

Global Anaplastic Large Cell Lymphoma Drugs Market Insights Forecast to 2030

Lymphoblastic Lymphoma Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Blood Tumor Treatment Market Research Report 2024

Global Mantle Cell Lymphoma Treatment Market Research Report 2025

Global Hematologic Malignancies Treatment Market Research Report 2024

Global Anaplastic Large Cell Lymphoma Treatment Market Insights Forecast to 2030

Global Mantle Cell Lymphoma Therapeutics Market Insights Forecast to 2030

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions